In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Antithrombotic prophylaxis in atrial fibrillation
Session

Congress : ESC CONGRESS 2015

Topic : Atrial Fibrillation

  • Session type : Moderated Posters
  • Date : 01 September 2015
  • Time : 10:00 - 11:00

7 presentations in this session

High burden of potentially avoidable stroke from discontinuation of warfarin therapy in non-valvular atrial fibrillation

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : S B Freedman (Sydney,AU)

Precipitated non valvular atrial fibrillation (NVAF): can we apply the CHA2DS2VASc score in the determination of the risk of stroke and death?

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : S Lang (Paris Cedex 12,FR)

Ablation of atrial fibrillation with uninterrupted NOAC treatment is not associated with severe peri- and postprocedural complications

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : C Wunderlich (Dresden,DE)

Warfarin therapy is associated with lower risk of dementia in patients with incident atrial fibrillation in a community based cohort

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : Y Hu (Rochester,US)

Prognosis in patients with atrial fibrillation and CHA2DS2-VASc score = 1 in a community based cohort study

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : L Fauchier (Tours,FR)

5-year real world experience using three LAA-closure devices

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : A Sedaghat (Bonn,DE)

Comparative cost-effectiveness of oral anticoagulants for stroke prevention in non-valvular atrial fibrillation patients in the UK

Congress : ESC Congress 2015

  • Session : Antithrombotic prophylaxis in atrial fibrillation
  • Speaker : T Lanitis (London,GB)

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are